A phase II single-blind, randomized, placebo-controlled trial to study the efficacy and safety of Study Drug administered as adjunctive treatment to patients with acquired thrombotic thrombocytopenic purpura.
RARE DISEASES NEWSLETTER Volume 6, May 2017
This quarterly publication will keep you up to date on PRA’s Rare Disease Team focus, achievements, and new initiatives.
Rare Disease Fact Sheet
Clinical development involving rare diseases poses a unique set of medical, scientific, and operational challenges. PRA understands these challenges…
The Fight Against Rare Diseases
Collectively, rare diseases represent a large medical challenge. While most have no cure, the appropriate treatment can greatly improve quality of…